Linda Johnson, Abstract Co-Author: Nothing to Disclose

Harsh Agarwal, Abstract Co-Author: Employee, Koninklijke Philips NV

Kinzya Bernice Grant MD, Abstract Co-Author: Nothing to Disclose

Marcelino Bernardo BS, Abstract Co-Author: Nothing to Disclose

Sandeep Sankineni MD, Presenter: Nothing to Disclose

Cindy Chau, Abstract Co-Author: Nothing to Disclose

William Dahut, Abstract Co-Author: Nothing to Disclose

Maria Merino MD, Abstract Co-Author: Nothing to Disclose

Bradford J. Wood MD, Abstract Co-Author: Researcher, Koninklijke Philips NV Researcher, Celsion Corporation Researcher, BTG International Ltd Researcher, , W. L. Gore & Associates, Inc Researcher, Delcath Systems, Inc Pending research funded, Perfint Healthcare Pvt Ltd Patent agreement, VitalDyne, Inc Intellectual property, Koninklijke Philips NV Intellectual property, BTG International Ltd

Peter Pinto, Abstract Co-Author: Nothing to Disclose

William Douglas Figg Pharm D, MBA, Abstract Co-Author: Nothing to Disclose

Peter L. Choyke MD, Abstract Co-Author: Researcher, Koninklijke Philips NV Researcher, General Electric Company Researcher, Siemens AG Researcher, iCAD, Inc Researcher, Aspyrian Therapeutics, Inc Researcher, ImaginAb, Inc Researcher, Aura

Baris Turkbey MD, Abstract Co-Author: Nothing to Disclose

The organic anion transporter polypeptide 1B3 (OATP1B3) is a testosterone transporter that is expressed de novo in prostate cancer and represents a possible mechanism of tumor growth. It represents an important prognostic indicator since OATP1B3 expression correlates with Gleason score and is associated with a decreased overall survival rate. Gadoxetate disodium (Eovist) is a MRI contrast agent that is a substrate for OATP1B3, allowing visualization of OATP1B3+ tumors on MRI. The purpose of this study is to determine if gadoxetate disodium-enhanced MRI can be utilized as a biomarker in patients with localized and metastatic disease.

Preliminary results include 8 patients with localized prostate cancer and 1 patient with metastatic CRPC (accrual is still continuing), with a mean age of 66 years and mean PSA of 12.68 ng/ml, all of whom had gadoxetate disodium-enhanced multi-parametric MRI scans obtained at 3 Tesla using a 32-channel cardiac coil. Gadoxetate disodium was administered intravenously and T1 TSE imaging was obtained at 10, 20, 40, and 60 minutes post injection. Post injection T1 TSE images were compared with pre-contrast images for each patient. Relative enhancement ratios were calculated over the tumor region for each patient at the 4 post-injection time points. Two-tailed Student’s t-test was used to compare signal enhancement between localized and metastatic cancer patients. Verification of OATP1B3 expression by immunohistochemistry will be performed in single batch once accrual of this trial is completed.

Mean enhancement ratios are shown in Table 1. There was a statistically significant difference between the enhancement ratios between localized and metastatic prostate cancer patients at 10 and 20 minutes post-injection gadoxetate disodium-enhanced MRI.

There is a significant difference between gadoxetate disodium enhancement in localized disease and metastatic CRPC. Gadoxetate disodium-enhanced MRI can help in determining OATP1B3 expression status of prostate cancer lesions.

Gadoxetate disodium-enhanced MRI may provide additional prognostic information, which can assist in risk stratification of patients with localized and metastatic prostate cancer.

Johnson, L, Agarwal, H, Grant, K, Bernardo, M, Sankineni, S, Chau, C, Dahut, W, Merino, M, Wood, B, Pinto, P, Figg, W, Choyke, P, Turkbey, B, Utility of Gadoxetate Disodium (Eovist)-enhanced MRI in Prostate Cancer Imaging.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14015883.html